Imidazopyrazinamine phenyl derivative and use thereof
View Patent ↗Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.
1. An imidazopyrazinamine phenyl derivative having a structure represented by general formula (I), a pharmaceutically acceptable salt or hydrate thereof,
wherein: Z is selected from NH, C═O or O;
R 1 is a benzene ring, a six-membered heteroaromatic ring having 1 or 2 nitrogens, which is optionally substituted with 0-2 C1-C4 alkyls;
R 2 is H, C1-C4 alkyl or halogen;
R 3 is
wherein R 4 is C(O)C≡CR 5 or C(O)CH═CHR 5 , and R 5 is H or C1-C4 alkyl.
2. The imidazopyrazinamine phenyl derivative according to claim 1 , a pharmaceutically acceptable salt or hydrate thereof, wherein R 2 is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
3. The imidazopyrazinamine phenyl derivative according to claim 1 , a pharmaceutically acceptable salt or hydrate thereof, wherein R 3 is
4. The imidazopyrazinamine phenyl derivative according to claim 1 , a pharmaceutically acceptable salt or hydrate thereof, wherein R 5 is H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
5. The imidazopyrazinamine phenyl derivative according to claim 1 , a pharmaceutically acceptable salt or hydrate thereof, wherein the imidazopyrazinamine phenyl derivative is one of the compounds represented by the following structural formulas:
6. A method for treating an indication/disease associated with BTK functions, the method comprising administering the imidazopyrazinamine phenyl derivative having a structure represented by general formula (I) according to claim 1 , a pharmaceutically acceptable salt or hydrate thereof, wherein the indication/disease associated with BTK functions is B cell lymphoma.